Changzhou Ruiming Pharmaceutical Co Ltd.

Main purpose: Using tamsulosin hydrochloride sustained-release capsules (specification: 0.2 mg) developed by Changzhou Ruiming Pharmaceutical Co., Ltd. as the test preparation, and tamsulosin hydrochloride sustained-release capsules (trade name: Harle®, specification: 0.2 mg) produced by Astellas Pharma (China) Co., Ltd. as the reference preparation, the relative bioavailability in healthy humans was compared to study the human bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation and reference preparation (trade name: Harle®) of tamsulosin hydrochloride sustained-release capsules in healthy subjects.

Main research purpose: Using levamlodipine besylate tablets (specification: 5 mg) developed by Changzhou Ruiming Pharmaceutical Co., Ltd. as the test preparation, according to the relevant provisions of bioequivalence studies, the relative bioavailability of amlodipine besylate tablets (specification: 10 mg, reference preparation, trade name: Norvasc®) produced by Pfizer Pharmaceuticals Co., Ltd. was compared in healthy humans, and the human bioequivalence of the two preparations was investigated. Secondary research purpose: To compare the safety of the test preparation levamlodipine besylate tablets and the reference preparation amlodipine besylate tablets (trade name: Norvasc®) in healthy subjects.